Our Approach: JCI is blending a mix of a traditional outreach and recruitment methods with an innovative media strategy to expand CBDA membership and position them as an industry authority.
Our Challenge: While sales of products containing hemp-derived cannabidiol (CBD) have been booming in the US, the industry is operating in a quasi-legal state as they wait for the FDA to finish its regulatory framework and for Congress to pass new legislation. To date, there have been only modest efforts to unite industry interests and communicate a consensus to policymakers, a void that a new industry trade group, the CBD Association, aims to fill. JCI is working with CBDA to bring together the disparate elements of growers, processors, suppliers, manufacturers, brand owners, retailers, and other associated businesses and best represent their interests at all levels of government while also promoting their products to consumers.
JCI is blending a mix of a traditional outreach and recruitment methods with an innovative media strategy to expand CBDA membership and position them as an industry authority. CBDA is set to be the leading industry trade group in the coming years.
Our Results: CBDA is on a promising trajectory, and is poised to play an instrumental role in the ongoing policy and legislative shifts around hemp and cannabis. With JCI’s continued support, CBDA is set to be the leading industry trade group in the coming years.
The association works hard in support of this constantly evolving sector. It will seek to improve standards, raise safety, provide regulatory information and encourage research as well as acting as counterpoint to evolving government policies.
The Cannabis Trades Association (CTA) is Europe’s largest trade body representing the interests of the cannabis and hemp industry. As such, it provides a forum for business members working in the same industry.
Buying from a CTA member is becoming even more important. For example, in the absence of a single regulatory code for businesses to adhere to, the CTA operates a code of conduct that the entire membership sign up to annually. This is necessary for introduction to payment providers, insurance brokers and banks.
The report authors call for a dedicated agency to licence and oversee the industry; a new centre of excellence to fund, synthesise and promulgate the best new clinical evidence to boost the UK’s nascent medicinal cannabis market; and urgent reform of licensing policy to steer and harness the emerging scientific evidence across the whole spectrum: from agri-science and plant genetics, to novel synthetics, new therapies and clinical trials.
The report, called Green Shoots – Sowing The Seeds Of The New UK Cannabis Industry, argued that the UK market represents a key growth sector for the UK and it is time for the government to adopt a proactive strategy to seize opportunities in cannabinoids.
The body’s new report, jointly written with the Centre for Medicinal Cannabis (CMC), concludes that the UK now has the most evolved regulatory framework in the world for CBD, citing recent interventions by the Foods Standards Agency to consider what are safe and tolerable levels of THC contained in products. The FSA began formally accepting Novel Foods applications for CBD products from January 2021.
Related tags: Cbd
Image: Getty/Sarah Pender
“The size of this cannabinoid sector is now impossible to ignore. Today’s report reveals that sales of CBD products up to the year end of April 2021 are valued at £690m, almost a third higher than our last projection in 2019,” said CMC and ACI co-founder Paul Birch, adding: “Almost without notice and certainly by accident rather than design, the UK has improbably become the world’s second largest consumer cannabinoids market.”